CLOs on the Move


 
DMC is leading the low cost sustainable transformation of multiple product markets.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.dmcbio.com
  • 2477 55th St, Suite 120
    Boulder, CO USA 80303
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Mo Bio Labs

Mo Bio Labs is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regenesis Biomedical

Regenesis Biomedical is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Virtual Radiologic Corporation

Virtual Radiologic (vRad) is a technology-enabled national radiology practice working in partnership with local radiologists and hospitals to optimize radiology’s pivotal role in patient care. vRad’s more than 400 radiologists serve 2,000+ facilities, reading 7 million studies annually. Delivering access to extensive subspecialty coverage, vRad contributes to improved quality of patient care. And with its next-generation technology, vRad enhances productivity, helping to lower the overall cost of care while expediting time to accurate diagnosis and treatment.

Aeovian Pharmaceuticals

We are a San Francisco Bay Area-based research stage biopharmaceutical company aiming to discover, develop and commercialize innovative therapeutics for the treatment of rare and age-related diseases. We are developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression, such as oxidative, cellular and environmental stress.

Merrimack Pharmaceuticals

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack has multiple oncology therapeutics in clinical development and additional candidates in late stage preclinical development. Merrimack has a New Drug Application under review for its lead product candidate, MM-398, for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.